David C. Yeomans, PhD
Co-Founder & Chief Scientific Officer
David brings over 40 years of experience in neuroscience, pharmacology, and translational drug development. A Professor Emeritus at Stanford University, where he directed pain research for more than two decades, he has pioneered therapeutic approaches spanning gene therapy, transcription factor targeting, and novel drug delivery technologies. His research has led to numerous NIH-funded programs, clinical trials, patents, and commercialized medical technologies. Notably, two drugs he co-invented are currently under clinical development by public pharmaceutical companies. David was instrumental in establishing the therapeutic potential of transcription factor decoys, including the development of candidates advanced into clinical studies. A co-founder of Core Biotherapeutics, he left his tenured position at Stanford in the fall of 2026 in order to join the company full-time as Chief Scientific Officer, bringing deep expertise in translating breakthrough biological discoveries into innovative therapeutics.